Elsevier

Atherosclerosis

Volume 235, Issue 1, July 2014, Pages 21-30
Atherosclerosis

Review
Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunction

https://doi.org/10.1016/j.atherosclerosis.2014.04.003Get rights and content
Under a Creative Commons license
open access

Highlights

  • We review current understanding of lysosomal acid lipase deficiency (LAL-D).

  • We provide recommendations to guide the timely diagnosis of LAL-D.

  • A diagnostic algorithm is proposed.

  • Lipidologists and other clinicians should be aware of the hallmarks of the disease.

Abstract

Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive lysosomal storage disease caused by deleterious mutations in the LIPA gene. The age at onset and rate of progression vary greatly and this may relate to the nature of the underlying mutations. Patients presenting in infancy have the most rapidly progressive disease, developing signs and symptoms in the first weeks of life and rarely surviving beyond 6 months of age. Children and adults typically present with some combination of dyslipidaemia, hepatomegaly, elevated transaminases, and microvesicular hepatosteatosis on biopsy. Liver damage with progression to fibrosis, cirrhosis and liver failure occurs in a large proportion of patients. Elevated low-density lipoprotein cholesterol levels and decreased high-density lipoprotein cholesterol levels are common features, and cardiovascular disease may manifest as early as childhood. Given that these clinical manifestations are shared with other cardiovascular, liver and metabolic diseases, it is not surprising that LAL-D is under-recognized in clinical practice. This article provides practical guidance to lipidologists, endocrinologists, cardiologists and hepatologists on how to recognize individuals with this life-limiting disease. A diagnostic algorithm is proposed with a view to achieving definitive diagnosis using a recently developed blood test for lysosomal acid lipase. Finally, current management options are reviewed in light of the ongoing development of enzyme replacement therapy with sebelipase alfa (Synageva BioPharma Corp., Lexington, MA, USA), a recombinant human lysosomal acid lipase enzyme.

Keywords

Cholesteryl ester storage disease
Dyslipidaemia
Hepatomegaly
Lysosomal acid lipase deficiency
Wolman disease

Cited by (0)